A major breakthrough in cancer treatment has been approved by the U.S. Food and Drug Administration (FDA) for patients with the most aggressive form of pancreatic cancer. The FDA has given the green light to a new drug called Rasonque (daraxonrasib), developed by Revolution Medicines. This is the first treatment designed specifically to target a family of genes called RAS, which plays a key role in driving the growth of pancreatic cancer and many other cancers. Until now, patients with metastatic pancreatic ductal cancer, the most common and deadly type of pancreatic cancer, had limited treatment options, mainly relying on chemotherapy given through an IV. The approval of Rasonque is based on strong results from a large clinical trial, which showed that this oral medication nearly doubled the average survival time for these patients. In the trial, patients taking Rasonque lived an average of 13.2 months, compared to just 6.7 months for those receiving standard chemotherapy. This is a significant improvement, as pancreatic cancer is often diagnosed late, making treatment much more challenging. The drug works by blocking multiple types of RAS proteins, which are mutated in many cancers, including pancreatic cancer, non-small cell lung cancer, and colorectal cancer. Speaking about the approval, Dr. Brian Wolpin, who led the trial, explained that despite RAS being a common target for decades, this is the first time patients have had access to a treatment that directly inhibits it. Dr. Angelo de Claro, Director of the FDA’s Oncology Center of Excellence, described the results as ‘unprecedented’ for a disease that has historically been very hard to treat. The FDA’s Acting Commissioner, Kyle Diamantas, also emphasized that Rasonque provides a much-needed new option for patients facing this difficult cancer. Dr. Anna Berkenblit, Chief Scientific and Medical Officer of the Pancreatic Cancer Action Network, added that this drug is likely to become a new standard of care for adults with metastatic pancreatic cancer who have already tried other treatments or cannot tolerate more intensive therapy. This approval marks an important step forward in precision medicine, offering hope to patients with one of the most challenging cancers to treat.